Definium Therapeutics, Inc. DFTX
Set alert
36.33 USD -1.63 -4.29%
At close · Oct 30
36.36 +0.03 +0.09%
After hours · Oct 30, 7:24 PM ET
35.87 Day range 37.90
10.68 52-week range 48.45
- YTD
- +171.32%
- 1 year
- +171.32%
- Open
- 37.24
- Prev close
- 37.96
- Mkt cap
- 4.88B
- Vol
- 1.08M
- Avg vol
- 2.17M
- EPS
- -3.43
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 35.87
- High
- 37.90
- Forward P/E
- -18.72
- Beta
- 2.19
- Short ratio
- 4.32
- Inst. own
- 88.54%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 9, 2026
- 50-d avg
- 37.95
- 200-d avg
- 29.50
- 1y target
- 72.56
Key statistics
- Market cap
- 4.88B
- Enterprise value
- 4.05B
- Trailing P/E
- 0.00
- Forward P/E
- -18.72
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 5.31
- EPS (TTM)
- -3.43
- Beta
- 2.19
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 7.61M
- Total cash
- 1.08B
- Total debt
- 36.47M
- Return on equity
- -64.09%
- Shares outstanding
- 134.37M
- Short % of float
- 7.52%
- 50-day average
- 37.95
- 200-day average
- 29.50
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 72.56 +99.7% upside
Now 36.33
- Target (low)
- 55.00
- Target (mean)
- 72.56
- Target (high)
- 91.00
Ratings (0m) 19 19 buy · 0 hold · 0 sell
- Strong buy5
- Buy14
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 9, 2026
Expected Nov 9, 2026. Consensus EPS estimate -0.56065.
Financials — quick view
DFTX Revenue — quarterly 0
DFTX Net income — quarterly -158.99M
DFTX EPS — quarterly -1.44
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 9, 2026 | Sep 30, 2026 | -0.56294 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.54102 | -1.44 | -0.90 | -166.16% |
| May 7, 2026 | Mar 31, 2026 | -0.47 | -0.71 | -0.24 | -51.06% |
| Feb 26, 2026 | Dec 31, 2025 | -0.48368 | -0.51 | -0.03 | -5.44% |
| Nov 6, 2025 | Sep 30, 2025 | -0.52 | -0.78 | -0.26 | -50.00% |
| Jul 31, 2025 | Jun 30, 2025 | -0.38 | -0.50 | -0.12 | -31.58% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 9, 2026 | JP Morgan | init | — | Overweight |
| Sep 15, 2026 | Canaccord Genuity | main | Buy | Buy |
| Sep 15, 2026 | Baird | main | Outperform | Outperform |
| Sep 14, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 14, 2026 | Needham | reit | Buy | Buy |
| Sep 11, 2026 | RBC Capital | reit | Outperform | Outperform |
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- definiumtx.com
News
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics, Inc. (NASDAQ:DFTX) Stock Has Average Target Price of $66.00 According to Analysts
- Definium Therapeutics Announces New Employee Inducement Grants
- JP Morgan Initiates Coverage On Definium Therapeutics with Overweight Rating, Announces Price Target of $84
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
- Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
- Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study
- Definium Therapeutics' DT120 Hits Phase III Goals in Anxiety Study
- Definium Reports Second Phase III Success in Anxiety Disorder Program
Your note
Sign in to keep a note on DFTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARROW ROBERT B | Chief Executive Officer | Sale | Sep 24, 2026 | 2,213,090 |
| BRUHN SUZANNE LOUISE | Director | Stock Award(Grant) | Jun 10, 2026 | 24,289 |
| CRYSTAL ROGER | Director | Stock Award(Grant) | Jun 10, 2026 | 24,289 |
| GRYSKA DAVID W | Director | Stock Award(Grant) | Jun 10, 2026 | 19,900 |
| KARLIN DANIEL ROLLINGS | Officer and Director | Sale | Sep 24, 2026 | 792,846 |
| KREBS ANDREAS | Director | Stock Award(Grant) | Jun 10, 2026 | 19,773 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.36% | 11,232,834 | 408.15M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 5.35% | 7,188,888 | 261.21M | Jun 29, 2026 |
| Driehaus Capital Management, LLC | 5.09% | 6,845,276 | 248.72M | Jun 29, 2026 |
| Jupiter Topco LLC | 4.18% | 5,615,645 | 204.04M | Jun 29, 2026 |
| Capital World Investors | 3.99% | 5,367,723 | 195.04M | Jun 29, 2026 |
| FMR, LLC | 3.54% | 4,752,921 | 172.70M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| SmallCap World Fund Inc | 7.63% | 10,253,153 | 372.55M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.41% | 3,243,233 | 117.84M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.11% | 1,486,832 | 54.02M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.06% | 1,422,899 | 51.70M | Jul 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.96% | 1,287,318 | 46.77M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.87% | 1,170,713 | 42.54M | Sep 29, 2026 |